ENDONOVO THERAPEUTICS, INC. Net Income Loss

• ENDONOVO THERAPEUTICS, INC. showed a decrease of -495.0% in Net Income Loss from 2021 to 2022.
• This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
• XBRL data for this metric is available from 2010 to 2022 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2011: $0.00 | Q4 2011: -$442.1 thousand | Q1 2012: -$430.8 thousand | Q2 2012: -$430.6 thousand | Q3 2012: -$392.9 thousand | Q3 2013: -$452.4 thousand | Q2 2014: -$202.7 thousand | Q3 2014: $94.6 thousand | Q2 2015: -$557.7 thousand | Q3 2015: -$1.28 million | Q1 2016: -$903.5 thousand | Q2 2016: -$1.45 million | Q3 2016: -$2.22 million | Q1 2017: -$7.76 million | Q2 2017: $1.86 million | Q3 2017: -$6.67 million | Q1 2018: -$618.9 thousand | Q2 2018: -$1.25 million | Q3 2018: -$5.95 million | Q1 2019: -$2.41 million | Q2 2019: -$7.84 million | Q3 2019: -$1.41 million | Q1 2020: $4.34 million | Q2 2020: -$1.63 million | Q3 2020: -$1.07 million | Q1 2021: -$2.68 million | Q2 2021: -$1.30 million | Q3 2021: -$1.52 million | Q1 2022: -$2.41 million | Q2 2022: -$2.53 million | Q3 2022: -$603.4 thousand | Q1 2023: $7.23 million | Q2 2023: $2.06 million | Q3 2023: -$766.2 thousand.
• Over the full 11 years of available data (2010 to 2022), ENDONOVO THERAPEUTICS, INC.'s Net Income Loss has declined by 26,520.8%.
• Historical annual values: Fiscal year 2022: -$18.47 million | Fiscal year 2021: -$3.10 million | Fiscal year 2020: -$395.6 thousand | Fiscal year 2019: -$17.31 million | Fiscal year 2018: -$6.44 million | Fiscal year 2017: -$10.81 million | Fiscal year 2016: -$5.32 million | Fiscal year 2015: -$6.77 million | Fiscal year 2014: -$959.5 thousand | Fiscal year 2011: -$94.1 thousand | Fiscal year 2010: -$69.4 thousand.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026